1. Home
  2. MMS vs PGEN Comparison

MMS vs PGEN Comparison

Compare MMS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maximus Inc.

MMS

Maximus Inc.

HOLD

Current Price

$63.31

Market Cap

3.2B

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$6.18

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMS
PGEN
Founded
1975
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.8B
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
MMS
PGEN
Price
$63.31
$6.18
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
★ $92.50
$13.65
AVG Volume (30 Days)
647.7K
★ 4.6M
Earning Date
11-19-2026
11-12-2026
Dividend Yield
★ 2.08%
N/A
EPS Growth
★ 10.42
N/A
EPS
★ 5.45
0.03
Revenue
★ $2,392,236,000.00
$230,981,000.00
Revenue This Year
N/A
$2,365.68
Revenue Next Year
$2.89
$85.75
P/E Ratio
★ $11.68
$212.83
Revenue Growth
N/A
★ N/A
52 Week Low
$51.04
$3.04
52 Week High
$100.00
$8.98

Technical Indicators

Market Signals
Indicator
MMS
PGEN
Relative Strength Index (RSI) 71.39 34.75
Support Level $56.00 $6.08
Resistance Level $70.49 $7.30
Average True Range (ATR) 1.84 0.38
MACD 0.73 -0.18
Stochastic Oscillator 94.55 2.57

Price Performance

Historical Comparison
MMS
PGEN

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: